Literature DB >> 7797920

Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates.

S Chou1, S Guentzel, K R Michels, R C Miner, W L Drew.   

Abstract

Cytomegalovirus (CMV) isolates from subjects who received ganciclovir therapy were tested for susceptibility to ganciclovir by a plaque reduction assay. Results were correlated with restriction enzyme and sequence analysis of the CMV UL97 phosphotransferase gene. Of the 30 isolates, 20 had one or more mutations in UL97 affecting amino acid encoding at codons 460, 520, or 591-596. All 20 were resistant to ganciclovir, with an IC50 of > 6.0 microM (range, 6.7-50.0). The remaining 10 isolates had no mutations at these loci; 8 were susceptible to ganciclovir while the other 2 were borderline resistant (IC50s, 6.6 and 7.2 microM). None of 40 control CMV isolates from untreated subjects contained any amino acid changes at these loci. The three most common mutations at codons 460, 594, and 595 were detected by restriction digest analysis in 16 (80%) of 20 isolates and in 16 (73%) of 22 isolates with ganciclovir IC50s > 6.0 microM. These results indicate that the majority of ganciclovir-resistant clinical isolates contain diagnostically useful mutations in UL97.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7797920     DOI: 10.1093/infdis/172.1.239

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency.

Authors:  D G Wolf; I Yaniv; S Ashkenazi; A Honigman
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir.

Authors:  S Chou; C L Meichsner
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

3.  Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients.

Authors:  Raymund R Razonable; Carlos V Paya; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories.

Authors:  S Chou; N S Lurain; A Weinberg; G Y Cai; P L Sharma; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Cytomegalovirus retinitis successfully treated with ganciclovir implant in a patient with blood ganciclovir resistance and ocular ganciclovir sensitivity.

Authors:  N K Bakshi; G A Fahle; I Sereti; H Wiley; R B Nussenblatt; H N Sen
Journal:  Eye (Lond)       Date:  2012-02-10       Impact factor: 3.775

6.  Detection of Two Drug-Resistance Mutants of the Cytomegalovirus by High-Resolution Melting Analysis.

Authors:  Xiao-Fan Chen; Tian-Run Li; Hong Yang; Yong Shao; Jie Zhang; Wei Zhang; Bo Yu; Zhun Wei; Bo Wu; Lin Yu
Journal:  J Clin Lab Anal       Date:  2015-05-13       Impact factor: 2.352

Review 7.  Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.

Authors:  H Hebart; L Kanz; G Jahn; H Einsele
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

8.  Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.

Authors:  J J McSharry; A McDonough; B Olson; C Talarico; M Davis; K K Biron
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

9.  Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.

Authors:  N S Lurain; A Weinberg; C S Crumpacker; S Chou
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

10.  Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.

Authors:  K Yeon Choi; B Sharon; H H Balfour; K Belani; T C Pozos; M R Schleiss
Journal:  J Clin Virol       Date:  2013-05-18       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.